ES2154633T3 - Procedimiento y composicion de prevencion de la enfermedad de lyme. - Google Patents

Procedimiento y composicion de prevencion de la enfermedad de lyme.

Info

Publication number
ES2154633T3
ES2154633T3 ES92111713T ES92111713T ES2154633T3 ES 2154633 T3 ES2154633 T3 ES 2154633T3 ES 92111713 T ES92111713 T ES 92111713T ES 92111713 T ES92111713 T ES 92111713T ES 2154633 T3 ES2154633 T3 ES 2154633T3
Authority
ES
Spain
Prior art keywords
lyme
disease
prevention
procedure
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92111713T
Other languages
English (en)
Inventor
Ian Dr Livey
Friedrich Dr Prof Dorner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter AG
Original Assignee
Baxter AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27419096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2154633(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter AG filed Critical Baxter AG
Application granted granted Critical
Publication of ES2154633T3 publication Critical patent/ES2154633T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PRESENTA UN INMUNOGENO EFECTIVO CONTRA LA BORRELIOSIS DE LYME EN LOS MAMIFEROS QUE COMPRENDE UNA PROTEINA PC HOMOGENEA DEL "B. BURGDORFERI" Y UN EXCIPIENTE FISIOLOGICAMENTE ACEPTABLE.
ES92111713T 1991-07-11 1992-07-09 Procedimiento y composicion de prevencion de la enfermedad de lyme. Expired - Lifetime ES2154633T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72724591A 1991-07-11 1991-07-11
US82416192A 1992-01-22 1992-01-22
US07/903,580 US6221363B1 (en) 1991-07-11 1992-06-25 Vaccine for the prevention of lyme disease

Publications (1)

Publication Number Publication Date
ES2154633T3 true ES2154633T3 (es) 2001-04-16

Family

ID=27419096

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92111713T Expired - Lifetime ES2154633T3 (es) 1991-07-11 1992-07-09 Procedimiento y composicion de prevencion de la enfermedad de lyme.

Country Status (17)

Country Link
US (2) US6221363B1 (es)
EP (1) EP0522560B2 (es)
JP (1) JP2611095B2 (es)
AT (1) ATE198489T1 (es)
AU (1) AU660178B2 (es)
CA (1) CA2073486C (es)
CZ (1) CZ280743B6 (es)
DE (1) DE69231619T3 (es)
DK (1) DK0522560T4 (es)
ES (1) ES2154633T3 (es)
FI (1) FI107334B (es)
HR (1) HRP950174B1 (es)
HU (1) HU219772B (es)
MX (1) MX9204078A (es)
NO (1) NO304546B1 (es)
SI (1) SI9200143B (es)
SK (1) SK217292A3 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872550B1 (en) * 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
US6303129B1 (en) * 1992-07-28 2001-10-16 Rx Technologies Production of borrelia burgdorferi vaccine, product produced thereby and method of use
JPH08509371A (ja) * 1993-04-29 1996-10-08 イムノ・アクチェンゲゼルシャフト ライム病の予防及び治療のためのＯｓｐＣ抗原ワクチンの免疫原性製剤及びかかる抗原の調製のための組換え方法
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
US6316005B1 (en) 1994-04-11 2001-11-13 Solvay Animal Health, Inc. Borrelia burgdorferi bacterin
US6087097A (en) * 1994-05-12 2000-07-11 Mayo Foundation For Medical Education And Research PCR detection of Borrelia burgdorferi
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
CN1285608C (zh) * 1995-09-22 2006-11-22 康诺特实验室有限公司 副流感病毒糖蛋白和疫苗
EP0880543A4 (en) * 1995-10-26 2000-08-02 Rhode Island Education ANTIGENS AS VACCINE CANDIDATES FOR THE SPICK-INDUCED LYME DISEASE SPIROCHETES (BORRELIA BURGDORFERI) BY TICK VECTORS (IXODES SCAPULARIS)
US6045804A (en) * 1996-03-07 2000-04-04 Mayo Foundation For Medical Educational Research Method for detecting B. burgdorferi infection
US6716574B2 (en) 1996-05-02 2004-04-06 Dako A/S Osp-C derived peptide fragments
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
GB9811219D0 (en) * 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
US6667038B1 (en) * 1999-04-21 2003-12-23 Boston Medical Center Corp. Prevention, diagnosis and treatment of lyme disease
DE60030859T2 (de) * 1999-06-18 2007-06-14 The Research Foundation Of State University Of New York Gruppen von borrelia burgdorferi, die lyme krankheit verursachen
AU2001285049A1 (en) 2000-08-18 2002-03-04 Brookhaven Sciences Associates, Llc Altered ospa of borrelia burgdorferi
US7442391B2 (en) 2002-01-25 2008-10-28 Integrated Botanical Technologies, Llc Bioactive botanical cosmetic compositions and processes for their production
US8277852B2 (en) 2002-01-25 2012-10-02 Akzo Nobel Surface Chemistry Llc Bioactive botanical cosmetic compositions and processes for their production
PL1722805T3 (pl) * 2004-01-12 2014-08-29 Akzo Nobel Surface Chemistry Llc Biologicznie czynne kompozycje z roślin Theacea oraz sposoby ich wytwarzania i zastosowanie
KR20080091233A (ko) 2006-01-19 2008-10-09 도요 세이칸 가부시키가이샤 커플러 및 연료 전지용의 연료 카트리지
BRPI0719360B1 (pt) * 2006-11-03 2016-09-06 Intervet Int Bv vacina da doença de lyme canina, e, uso de organismos de uma genoespécie de borrelia
US8293876B2 (en) 2007-02-22 2012-10-23 Baxter International Inc. Method of purification of hydrophobic proteins
WO2009131665A1 (en) * 2008-04-22 2009-10-29 Research Foundation Of State University Of New York Borrelia burgdorferi cell envelope protein array
JP2013511530A (ja) * 2009-11-17 2013-04-04 アバクシス， インコーポレイテッド ライム病抗体の検出のためのペプチドおよび方法
ES2969952T3 (es) 2011-04-22 2024-05-23 Wyeth Llc Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos
US8758772B2 (en) 2011-11-04 2014-06-24 Abaxis, Inc. Peptides and methods for the detection of lyme disease antibodies
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
KR102451333B1 (ko) * 2018-10-22 2022-10-06 주식회사 엘지화학 마이크로비드 및 그 제조방법
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4767622A (en) * 1983-08-19 1988-08-30 University Of Illinois Method and materials for development of immunological responses protective against malarial infection
US4601903A (en) * 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4888276A (en) 1986-06-26 1989-12-19 Minnesota Mining And Manufacturing Company Method and composition for the diagnosis of Lyme disease
US4721617A (en) 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
US5192540A (en) * 1988-04-19 1993-03-09 American Cyanamid Company Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine
DE3818013A1 (de) 1988-05-27 1989-11-30 Henkel Kgaa Gewebeweichmachungsmittel
IT1223777B (it) * 1988-08-18 1990-09-29 Gevipi Ag Rubinetto a due uscite con inversore a depressione
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
DK0506868T4 (da) * 1989-12-22 2004-04-26 Mikrogen Molekularbiol Entw Immunologisk aktive proteiner fra Borrelia burgdorferi, tilhørende testkits og vaccine
DE3942728C1 (en) 1989-12-22 1991-05-23 Mikrogen Molekularbiologische Entwicklungs-Gmbh, 8000 Muenchen, De New immunologically active proteins derived from Borelia burgdorferiensity polyethylene vessel and a high density polyethylene sealing cap - useful as vaccine and for quick accurate diagnosis of Borelia infections
WO1991013630A1 (en) 1990-03-05 1991-09-19 The United States Of America, Represented By The Secretary, United States Department Of Commerce ANTIGENIC PROTEINS OF $i(BORRELIA BURGDORFERI)
EP1016416A3 (en) * 1990-07-06 2002-10-23 Wyeth Vaccine against lyme disease and a challenge model for evaluating vaccine efficacy

Also Published As

Publication number Publication date
CA2073486A1 (en) 1993-01-12
FI923175A0 (fi) 1992-07-09
FI923175L (fi) 1993-01-12
CZ217292A3 (en) 1993-01-13
HUT66525A (en) 1994-12-28
DE69231619T2 (de) 2001-05-31
EP0522560B2 (en) 2006-12-20
DE69231619D1 (de) 2001-02-08
DK0522560T3 (da) 2001-03-05
EP0522560A3 (en) 1994-05-11
NO922746L (no) 1993-01-12
FI107334B (fi) 2001-07-13
AU1934992A (en) 1993-01-14
JPH072696A (ja) 1995-01-06
EP0522560A2 (en) 1993-01-13
NO304546B1 (no) 1999-01-11
US6221363B1 (en) 2001-04-24
SI9200143A (en) 1993-03-31
HU219772B (hu) 2001-07-30
CZ280743B6 (cs) 1996-04-17
HRP950174B1 (en) 2001-08-31
NO922746D0 (no) 1992-07-10
CA2073486C (en) 2002-07-02
EP0522560B1 (en) 2001-01-03
MX9204078A (es) 1993-04-01
ATE198489T1 (de) 2001-01-15
HRP950174A2 (en) 1997-08-31
HU9202289D0 (en) 1992-10-28
US5530103A (en) 1996-06-25
SK279250B6 (sk) 1998-08-05
SI9200143B (en) 2001-06-30
DE69231619T3 (de) 2007-07-12
SK217292A3 (en) 1998-08-05
AU660178B2 (en) 1995-06-15
JP2611095B2 (ja) 1997-05-21
DK0522560T4 (da) 2007-04-10

Similar Documents

Publication Publication Date Title
CA2073486A1 (en) Composition for the prevention of lyme disease and use for
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
NL300389I1 (nl) Thiofeensulfonamiden die bruikbaar zijn als carbo-anhydraseremmers.
DE69228747D1 (de) Medizinische/chirurgische vorrichtungen
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
IT1256652B (it) Procedimento per la preparazione di una composizione farmaceutica che abbassa selettivamente il livello di lipidi del sangue
DK0491085T3 (da) Tandlæge-patientstol
MX9302927A (es) Nuevos peptidos, la preparacion y utilizacion de los mimos.
SE8804628D0 (sv) New compounds
DK0629400T3 (da) Idebenon-holdige præparater til behandling af Alzheimer's syge
ZA879458B (en) Medicaments
ITTO910664A0 (it) Procedimento e dispositivo per la guida dello slittone di una pressa.
ES2026304A6 (es) Procedimiento de fabricacion de una forma de dosificacion de nicardipina.
SE9502219D0 (sv) Novel medical use
DK0466833T3 (da) Insekticide og synergistiske miticide midler
ITMI922571A0 (it) Procedimento per la preparazione di un cassetto a stantuffo nonche' dispositivo per l'attuazione del procedimento
IT1092132B (it) Vite autofilettante nonche' procedimento per la sua fabbricazione e ganascia di cilindratura per l'attuazione del procedimento
IT1277348B1 (it) Composizione farmaceutica per abbassare la pressione del sangue e procedimento per la sua preparazione
EP0876156A4 (en) COMPOSITIONS AND METHODS FOR THE APPLICATION OF ANTIGENS FOR BORRELIA BURGDORFERI
ES2161809T3 (es) Uso de factor proliferativo osteoblastico.
IT8520396A0 (it) Apparecchiatura per l'esecuzione di cure canalari nel campo della medicina dentale.
YU68592A (sh) Kompozicija za sprečavanje lajmske bolesti i postupak za dobijanje
IT9021199A0 (it) "agente per la defoliazione del cotone"
ITTN960015V0 (it) "schema anatomico del viso di una persona" per l'esecuzione completa ottimale di un occhiale da vista senza la presenza fisica della
KR890023991U (ko) 모니터의 영상 출력장치

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 522560

Country of ref document: ES